Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
67.295
0.225 (0.34%)
Market Cap: 12.83 Bil
Enterprise Value: 12.46 Bil
PE Ratio: 40.30
PB Ratio: 2.37
GF Score: 69/100 Biomarin Pharmaceutical Inc at RBC Global Healthcare Conference Transcript
May 19, 2020 / 05:55PM GMT
Release Date Price:
$93.89
(-1.54%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Hi, my name is Kennen MacKay, and I'm one of the Senior Biotechnology Analysts here at RBC. It's my great pleasure to keep our conference rolling and be -- and joined on the line with BioMarin Pharmaceuticals. From BioMarin, I have Dr. Hank Fuchs, the President of Worldwide Research and Development. Hank, thanks so much for joining us today.
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Thanks, Kennen. We appreciate the opportunity to participate in your virtual health care meeting today.
Questions & Answers
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Thank you. So obviously, an incredibly busy and a very functionally different time. Obviously, all of us are adjusting to work-from-home due to the coronavirus impact. Maybe we can just kick off the discussion with sort of your sense of where
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot